This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Sumitomo Pharma Co., Ltd.. Active years: 2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009
Title: Hiroyuki Hariu: Innovator in Cancer Vaccine Development
Introduction
Hiroyuki Hariu is a prominent inventor based in Sapporo, Japan. He has made significant contributions to the field of cancer research, particularly in the development of innovative cancer vaccines. His work focuses on harnessing the immune system to target cancer cells effectively.
Latest Patents
Hariu holds a patent for an HLA-A24 binding cancer antigen peptide derived from livin. This invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin, which binds to the HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs). The patent also includes a polynucleotide encoding the peptide and a cancer vaccine comprising the peptide or the polynucleotide. He has 1 patent to his name.
Career Highlights
Hariu is associated with Dainippon Sumitomo Pharma Co., Ltd., where he collaborates with other experts in the field. His work has been instrumental in advancing cancer treatment options and improving patient outcomes.
Collaborations
Hariu has worked alongside notable colleagues such as Noriyuki Sato and Toshihiko Torigoe. Their combined expertise has contributed to the success of various projects within the company.
Conclusion
Hiroyuki Hariu's innovative work in cancer vaccine development showcases his dedication to improving healthcare through scientific advancements. His contributions are paving the way for new treatment options in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile